Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. Issue 7 (July 2021)
- Record Type:
- Journal Article
- Title:
- Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. Issue 7 (July 2021)
- Main Title:
- Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study
- Authors:
- Laudenslager, Marci
Lazo, Mariana
Wang, Dan
Selvin, Elizabeth
Chen, Po-Hung
Pankow, James S.
Clark, Jeanne M. - Abstract:
- Abstract: Background: Inflammation is key in the pathogenesis of Nonalcoholic Fatty Liver Disease (NAFLD) – a common progressive liver disease. The soluble receptor for advanced glycation end products (sRAGE) attenuates inflammatory signaling; low levels of sRAGE are correlated with increased inflammation. Aim: We sought to describe associations between sRAGE and NAFLD. Methods: We conducted a cross-sectional analysis of 1088 Atherosclerosis Risk in Communities (ARIC) Study participants and used logistic regression to investigate the associations between sRAGE and NAFLD defined by elevated liver enzymes and fibrosis score. Results: In this community-based sample ( n = 1, 088, mean age 56 years, 61% female, 78% Caucasian), persons in the lowest vs. highest quartile of sRAGE had significantly higher odds of elevated ALT (OR 2.82, 95% CI 1.18-6.76) but not elevated AST (OR 1.16, 95% CI 0.45-2.99); persons in the lowest vs. highest quartile had significantly lower odds of elevated FIB-4 index (OR 0.56, 95% CI 0.37-0.84). Conclusions: We found an inverse cross-sectional association between sRAGE and liver inflammation; this is consistent with prior studies linking low sRAGE to inflammatory states. However, we observed a direct association between sRAGE and fibrosis. Our findings suggest that sRAGE is dynamic in NAFLD and patterns may vary with different stages of disease.
- Is Part Of:
- Digestive and liver disease. Volume 53:Issue 7(2021)
- Journal:
- Digestive and liver disease
- Issue:
- Volume 53:Issue 7(2021)
- Issue Display:
- Volume 53, Issue 7 (2021)
- Year:
- 2021
- Volume:
- 53
- Issue:
- 7
- Issue Sort Value:
- 2021-0053-0007-0000
- Page Start:
- 873
- Page End:
- 878
- Publication Date:
- 2021-07
- Subjects:
- Biomarkers -- Inflammation -- NAFLD -- Receptor for advanced glycation end products
Digestive organs -- Diseases -- Periodicals
Liver -- Diseases -- Periodicals
616.33005 - Journal URLs:
- http://www.sciencedirect.com/science/journal/15908658 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.dld.2021.02.005 ↗
- Languages:
- English
- ISSNs:
- 1590-8658
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3588.345600
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17324.xml